Home     About SABCS     Press Releases     Media     Event Photos     Past Symposia     Satellite Symposia     Patient Advocates     FAQs     Contact Us

Registration           Hotel           Support & Exhibits     2014 Overview           Program           Travel & Transportation          

Quick Links
Career Development Forum Reg Form
SABCS 2013 Program Book pdf

Schedule at a Glance
Daily Schedule:
Tue. 12/9/2014
Wed. 12/10/2014
Thu. 12/11/2014
Fri. 12/12/2014
Sat. 12/13/2014
Poster Sessions:
Poster Session 1
Poster Session 2
Poster Session 3
Poster Session 4
Poster Session 5
Poster Session 6
Poster Session OT1
Poster Session OT2
Poster Session OT3
Poster Discussions:
Poster Discussion 1
Poster Discussion 2
Poster Discussion 3
Poster Discussion 4
Poster Discussion 5
Poster Discussion 6

Program Schedule   >  Poster Sessions - Poster Session 1

Poster Session 1 
  Detection and Diagnosis: Axillary Staging and Sentinel Nodes
P1-01-01 The value of isosulphan blue dye in addition to isotope scanning in the identification of the sentinel lymph node in breast cancer patients with a positive lymphoscintigraphy: A randomised controlled trial (ISRCTN 98849733)
O'Reilly EA, Aucharaz N, Kelly G, Al Azawi D, Prichard RS, Evoy D, Rothwell J, Geraghty J, O'Doherty A, Skehan S, Quinn C, McDermott E. St Vincent's Healthcare Group, Elm Park, Dublin, Ireland; University College Dublin, Dublin, Ireland; St. Vincent's Healthcare Group, Elm Park, Dublin 4, Ireland; St Vincent's Healthcare Group, Elm Park, Dublin 4, Ireland.
P1-01-02 The SentiMag study: Sentinel node biopsy with superparamagnetic iron oxide vs. radioisotope
Thill M, Kurylcio A, Blechmann R, van Haasteren V, Grosse B, Berclaz G, Polkowski W, Hauser N. Breast Cancer Centre, Agaplesion Markus Hospital, Frankfurt, Germany; Medical University of Lublin, Lublin, Poland; Interdisciplinary Breast Cancer Centre, Kantonsspital Baden, Baden, Switzerland; Breast Centre Bern, Engeriedspital, Lindenhofgruppe, Bern, Switzerland.
P1-01-03 Interim analysis of the validation study on the clinical usefulness of the ICG fluorescence method for detecting sentinel lymph nodes in early breast cancer compared with the RI method (fICG-BR02)
Yasojima H, Sugie T, Masuda N, Kinoshita T, Sawada T, Yamauchi A, Kuroi K, Taguchi T, Bando H, Yamashiro H, Lee T, Shinkura N, Kato H, Ikeda T, Yoshimura K, Tada H, Ueyama H, Yokohashi Y, Toi M. National Hospital Organization Osaka National Hospital, Osaka, Japan; Kyoto University Hospital, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Showa University School of Medicine, Tokyo, Japan; The Tazuke-Kofukai Medical Research Institute Kitano Hospital, Osaka, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Tsukuba University Hospital, Tsukuba, Japan; Japanease Red Cross Kyoto Daiichi Hospital, Kyoto, Japan; Kyoto Breast Center Sawai Memorial Clinic, Kyoto, Japan; Kobe City Medical Center General Hospital, Kobe, Japan.
P1-01-04 Nodal patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy: Results of a secondary analysis of TBCRC 017
McGuire KP, De Los Santos JF, Cantor A, Forero A, Golshan M, Meric-Bernstam F, Horton JK, Amos KD, Hudis CA, Hylton NM, Meszoely IM, Nanda R, Hwang S. University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; University of Alabama at Birmingham, Birmingham, AL; Harvard Medical School, Boston, MA; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Duke University Medical School, Durham, NC; University of North Carolina Chapel Hill, Chapel Hill, NC; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California at San Francisco, San Francisco, CA; Vanderbilt Medical Center, Nashville, TN; University of Chicago, Chicago, IL; Duke University, Durham, NC.
P1-01-05 Withdrawn
P1-01-06 Elaboration of a nomogram to predict the non sentinel node status (NSN) in breast cancer (BC) patients with positive SN, intra-operatively assessed with OSNA (one step nucleic acid amplification) method
Di Filippo F, Gianarelli D, On Behalf of European and Italian OSNA Users. Regina Elena Cancer Institute Rome, Roma, Italy.
P1-01-07 Pre-operative selection of patients with limited disease of the axilla using ultrasonography of the axilla: Might additional lymph node dissection (ALND) be safely omitted in the future?
Moorman A, Bourez R, Heijmans H, Kouwenhoven E. Hospital Group Twente, Almelo, Netherlands; Hospital Group Twente, Hengelo, Netherlands.
P1-01-08 Diagnostic accuracy of pre-operative ultrasonographic evaluation of axillary lymph nodes in breast cancer patients: Is there a place for axillary ultrasonography in future nomograms?
Moorman A, Bourez R, de Leeuw D, Kouwenhoven E. Hospital Group Twente, Almelo, Netherlands.
P1-01-09 TRIAL VIRN-2012: 200 cases of sentinel lymph node (SLN) detection with fluorescence lymphangiography
Samorani D, Frisoni G, Fogacci T, Accardi FG. General and Breast Surgery - Santarcangelo Hospital, Santarcangelo di Romagna, Rimini, Italy.
P1-01-10 Sentinel lymph node-II biopsy in breast cancer: A novel method to accurately predict non-sentinel axillary lymph node status
Ballehaninna UK, Andaz C, Borgen PI. Maimonides Medical Center, Brooklyn, NY.
P1-01-11 The health economics of one step nucleic acid amplification for intraoperative sentinel lymph node analysis in breast cancer
King PM, Simmons F, Philip DJ, Iain BM, Rachel EE, Sheikh A. Royal Cornwall Hospital NHS Trust, Truro, Cornwall, United Kingdom.
P1-01-12 Intraoperative detection of sentinel lymph nodes in breast cancer patients using ultrasonography-guided direct indocyanine green dye-marking by real-time virtual sonography constructed with three-dimensional computed tomography-lymphography
Yamamoto S, Maeda K, Maeda N, Yoshimura K, Oka M. Yamaguchi University Graduate School of Medicine, Ube City, Yamaguchi, Japan.
P1-01-13 Intraoperative evaluation of sentinel lymph nodes using touch imprint cytology in patients with early-stage breast cancer: A series of 4367 procedures
Chen Y, Chen J, Chen J, Yang B, Li L, Huang X, Shao Z, Shen Z, Wu J. Shanghai Cancer Center, Fudan University, Shanghai, China; Shanghai Medical College, Fudan University, Shanghai, China. Ying Chen is a recipient of an Avon-AACR International Scholar-In-Training Award
P1-01-14 Extracorporeal shock wave therapy for lymphedema after axillary lymphadenectomy
Imboden S, Herzig D, Rabaglio M, Hohermuth R, Mueller MD, Günthert AR, Eser P, Schmid J-P. University Hospital and University of Berne, Berne, Switzerland.
P1-01-15 Relationship amongst sentinel lymph node pressure, volume, and breast cancer tumor size
Krasnick BA, Arbabi CN, Nathanson DS, Chitale DA. Henry Ford Health System, Detroit, MI.
P1-01-16 Prediction of non-sentinel lymph node status in breast cancer patients with sentinel lymph node metastases: Comparison of the MD Anderson, Cambridge and Helsinki nomograms in a cohort of 80 patients
Michalakis IV, Dunk L, Krupa J. University Hospitals of Leicester, Leicester, United Kingdom.
P1-01-17 Sentinel node biopsy for breast cancer: Intraoperative injection of radiocolloid
Vu HN, O'Connor PW, Shoemaker RR, Wan W, Fratkin MJ, Bear HD. Virginia Commonwealth University, Richmond, VA; Wayne State University Detroit Medical Center, Detroit, MI.
P1-01-18 Sentinel lymph node identifcation in breast cancer using methylene blue and patent blue: A randomized controlled trial
Vuthaluru S, Srivastava A, Misra M. All India Institute of Medical Sciences, New Delhi, Delhi, India. Seenu Vuthaluru is a recipient of an Avon-AACR International Scholar-In-Training Award
P1-01-19 Role of axillary clearance with tumor positive sentinel node in mastectomy group: Is the results of ACOSOG Z0011 trial adaptable to mastectomy patient?
You JY, Song EJ, Lee MH, Jung SY, Lee SY, Kang HS, Lee ES. Center for Breast Cancer, National Cancer Center, Goyang, Gyeonggi-do, Korea.
P1-01-20 Intra-operative sentinel node imaging with a portable gamma camera in breast cancer
Ghosh DB, Michalopoulos NV, Davidson T, Wickham C, Stafyla V, Banerjee SM, Jamali S, Williams NR, Keshtgar MR. University College London, Royal Free London NHS Foundation Trust, London, United Kingdom; Royal Free London NHS Foundation Trust, London, United Kingdom; Clinical Trials Group, UCL Division of Surgery and Interventional Science, Centre for Clinical Science and Technology, London, United Kingdom.
P1-01-21 Is it safe to skip intra-operative frozen section examination of sentinel lymph node for core biopsy-diagnosed DCIS?
Chan YHY, Ying MWL, Chan MCM, Cheung CY, Hung WK, Mak KL, Lui CY. Kwong Wah Hospital, Kowloon, Hong Kong.
P1-01-22 Which cytologically proven node-positive breast cancer patients can avoid axillary lymph dissection after neaodjuvant chemotherapy?
Karanlik H, Ilhan B, Fayda M, Yavuz E, Mudun A, Saip P, Eralp Y, Kurul S, Aydiner A. Istanbul University Institute of Oncology Surgical Oncology Unit, Turkey; Istanbul University Institute of Oncology, Turkey; Istanbul University Istanbul Faculty of Medicine, Turkey.
P1-01-23 Intraoperative optical coherence tomography for the assessment of metastatic disease in human lymph nodes
Marjanovic M, Adie SG, Nolan RM, Chaney EJ, Shemonski ND, South FA, Erickson-Bhatt SJ, Shelton RL, Bower AJ, Simpson DG, Ray PS, Cradock KA, Brockenbrough J, Liu G, Boppart SA. Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, Urbana, IL; University of Illinois College of Medicine and Carle Cancer Center, Urbana, IL; Carle Foundation Hospital, Urbana, IL.
P1-01-24 Preoperative ultrasound staging of the axilla superfluous peroperative examination of the sentinel node
Tjalma W, Van Berckelaer C, Van Goethem M, Verslegers I, Van Dam P. UZA, Edegem, Antwerp, Belgium.
P1-01-25 Predictive factors of micrometastases in the sentinel node of patients affected by invasive early breast cancer
Livi L, Meattini I, Bertocci S, Zei G, Cecchini S, Francolini G, Scotti V, De Luca Cardillo C, Orzalesi L, Casella D, Simoncini R, Nori J, Bianchi S, Biti G. University of Florence, Florence, Italy.
P1-01-26 The feasibility of SNIPE trial; sentinel lymph node biopsy vs. no-SLNB In patients with early breast cancer
Nadeem RM. Lancashire Teaching Hospitals NHS Foundation Trust, Chorley, United Kingdom.
P1-01-27 SentiMAG multicentre trial*: Comparison of sentinel node biopsy identification rates using a magnetic tracer vs. standard technique. * UKCRN ID 12178 (UK); NTR 3283 (Netherlands)
Douek M, Monypenny I, Klaase J, Kothari A, Zechmeister K, Brown D, Drew P, Wyld L, Garmo H, Castro F, Anninga B, Pankhurst Q, ten Haken B, Hall-Craggs MA, Pinder S, Purushotham A, On Behalf of the SentiMAG Trialists Group. King's College London, London, United Kingdom; Guy's & St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom; University Hospital of Wales at Llandough, Cardiff, United Kingdom; Medisch Spectrum Twente, Enschede, Netherlands; Norwich and Norfolk University Hospitals, Norwich, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; University of Sheffield, Sheffield, United Kingdom; University College London, London, United Kingdom; University College Hospital, London, United Kingdom.
  Detection and Diagnosis: Diagnostic Pathology
P1-02-01 Pre-analytical setting is critical for an assessment of the Ki-67 labeling index for breast cancer
Arima N, Toyozumi Y, Nishimura R, Osako T, Nishiyama Y, Nakano M, Fujisue M, Tashima R, Moriya T. Kumamoto City Hospital, Kumamoto, Japan; Kawasaki Medical University, Kurashiki, Okayama, Japan.
P1-02-02 Concordance of microarray based determination of ER, PR and HER2 receptor status and local IHC/FISH assessment in the prospective neo-adjuvant breast registry symphony trial (NBRST)
Beitsch P, Gittleman M, Akbari S, Stork-Sloots L, de Snoo F, Gibson J, Whitworth P. Dallas Surgical Group, Dallas, TX; Breast Care Specialists, Allentown, PA; Virginia Hospital Center, Arlington, VA; Agendia NV, Amsterdam, Netherlands; Agedia Inc, Irvine, CA; Nashville Breast Center, Nashville, TN.
P1-02-03 Clinical utility of combined brightfield HER2 gene-protein assay in IHC equivocal cases
Bhargava R, Dabbs DJ. Magee-Womens Hospital of UPMC, Pittsburgh, PA.
P1-02-04 Array based resolution of HER2 amplification status in breast carcinomas displaying apparent chromosome 17 aneusomy
Portier BP, Wang Z, Minca E, Lanigan C, Downs-Kelly E, Tubbs RR. Cleveland Clinic, Cleveland, OH.
P1-02-05 Identification of HER-2/neu amplification using amplicon based benchtop next generation sequencing
Portier BP, Patel K, Medeiros LJ, Singh R, Aldape KJ, Hamilton S, Luthra R, Routbort M. UT MD Anderson Cancer Center, Houston, TX.
P1-02-06 Assigning luminal A versus luminal B subtype using the Ki67 index in patients with hormone receptor positive (HR+) breast cancer enrolled in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
Wolf DM, Keck S, Yau C, Livasy C, Mori M, Baehner R, I-SPY 1 Investigators, van 't Veer L, Esserman L, Rugo H. University of California, San Francisco; University of North Carolina, Chapel Hill; Genomic Health, Redwood City; I-SPY 1 Trial.
P1-02-07 Discordance for low and intermediate levels (1+ or 2+ by IHC) of HER2 protein expression in the phase III PRESENT trial
Rugo HS, Melisko M, Ben-Baruch NE, Price Hiller J, Dahkil S, Sutton L, Mazanet R, Mittendorf E. University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Kaplan Medical Center, Rehovot, Israel; Cross Cancer Institute, Edmonton, AB, Canada; Cancer Center of Kansas, Wichita, KS; Galena Biopharma, Inc., Portland, OR; UT MD Anderson Cancer Center, Houston, TX.
P1-02-08 Papillary lesions of the breast on core biopsies: Should routine surgical excision be performed?
Ho CS, Yap WM, Chong BK. Tan Tock Seng Hospital, Singapore, Singapore.
P1-02-09 Positive predictive value (PPV) of the diagnosis of atypia in breast core biopsies: An audit of MSKCC breast pathology service
Conlon N, Gallagher M, Catalano J, Howard J, Tan LK. Memorial Sloan-Kettering Cancer Center, New York, NY.
P1-02-10 Variation in HER2 positive rates in California by geographic region: Implications for setting pathology laboratory benchmarks
Allison KH, Jensen KC, West RB, Clarke CA, Gomez SL, Kurian AW. Stanford University School of Medicine, Stanford, CA; Cancer Prevention Institute of California, Fremont, CA.
P1-02-11 Flat epithelial atypia on breast core biopsy: Is excision warranted?
Calhoun BC, White RL, Flippo-Morton T, Sarantou T, Gromet M, Sobel A, Livasy CA. Carolinas Pathology Group, Charlotte, NC; Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Charlotte Radiology, Charlotte, NC.
  Detection and Diagnosis: Circulating Markers
P1-03-01 Circulating CAIX as a biomarker in breast cancer
Brown-Glaberman U, Chalasani P, Livingston R, Iannone M, Marron M, Specht J, Stopeck A. University of New Mexico Cancer Center, Albuquerque, NM; University of Arizona Cancer Center, Tucson, AZ; Fred Hutchinson University of Washington Cancer Consortium, Seattle, WA.
P1-03-02 Peripheral blood mRNA signature may have the potential to detect early breast cancer patients in large screening process
Yang B, Xu Q, Ye X, Liu G, Shao Z, Meng X, Mougin B, Wu J. Fudan University Cancer Center, Shanghai, China; FUCH – bioMérieux Laboratory, Shanghai, China.
  Detection and Diagnosis: Circulating Tumor Cells
P1-04-01 Significance of circulating tumor cells in metastatic triple negative breast cancer: Results of an open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 tigatuzumab (TBCRC 019)
Paoletti C, Li Y, Muńiz MC, Kidwell KM, Aung K, Thomas DG, Brown ME, Abramson V, Irvin, Jr WJ, Lin NU, Liu M, Nanda R, Nangia J, Storniolo AM, Traina TA, Vaklavas C, Van Poznak CH, Wolff AC, Forero A, Hayes DF. University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD. Costanza Paoletti is a recipient of an AACR Scholar-In-Training Award
P1-04-02 Correlation between blood markers of hemostasis and circulating tumor cells (CTCs) in early breast cancer patients
Mego M, Karaba M, Minarik G, Benca J, Sedlackova T, Tothova L, Vlkova B, Cierna Z, Janega P, Manasova D, Luha J, Gronesova P, Pechan J, Fridrichova I, Celec P, Reuben JM, Cristofanilli M, Mardiak J. Faculty of Medicine, Comenius University, Bratislava, Slovakia (Slovak Republic); National Cancer Institute, Bratislava, Slovakia (Slovak Republic); Cancer Research Institute, Bratislava, Slovakia (Slovak Republic); Institute of Normal and Pathological Physiology, Bratislava, Slovakia (Slovak Republic); University of Texas, MD Anderson Cancer Center, Houston, TX; Thomas Jefferson University-Kimmel Cancer Center, Philadelphia, PA.
P1-04-03 Genome-wide analysis of copy number variations and mutation profiles of single circulating tumour cells using massively parallel paired-end sequencing
Peeters DJE, Kumar P, Van der Aa N, Rothé F, Theunis K, Op de Beeck K, Van Laere SJ, Vermeulen PB, van Dam PA, Vincent D, Desmedt C, Sotiriou C, Dirix LY, Ignatiadis M, Voet T. Translational Cancer Research Unit, Oncology Center, GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp/Antwerp University Hospital, Antwerp, Belgium; Laboratory of Reproductive Genomics, KU Leuven, Leuven, Belgium; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Single-Cell Genomics Centre, Wellcome Trust Sanger Institute, Hinxton-Cambridge, United Kingdom; These authors contributed equally to the data presented in this abstract; Joint Senior Authors.
P1-04-04 Towards methodology of detecting PIK3CA mutations on single cell level by massive parallel sequencing
De Laere B, Peeters D, van Schooneveld E, Salgado R, Vermeulen P, Dirix L, Van Laere S. Translational Cancer Research Unit, Oncology Center, GZA Hospitals Sint-Augustinus, Wilrijk, Antwerpen, Belgium; U Leuven, Leuven, Vlaams-Brabant, Belgium.
P1-04-05 Subpopulation heterogeneity demonstrated in circulating tumor cells isolated from breast cancer patients using ApoStream™, an antibody-independent cancer cell recovery device
Anderes KL, Melnikova VO, Gupta V, Hasegawa DK, Davis DW. ApoCell, Inc, Houston, TX.
P1-04-06 Discordance of the ER- and HER2-status on disseminated tumor cells compared to the primary tumor in patients with early breast cancer
Jaeger BAS, Finkenzeller C, Bock C, Majunke L, Jueckstock J, Andergassen U, Neugebauer J, Pestka A, Friedl T, Jeschke U, Janni W, Doisneau-Sixou S, Rack B. University Hospital Ulm, Ulm, Germany; Hospital of the Ludwig-Maximilians-University, Munich, Germany.
P1-04-07 Isolation and expression profiling of EpCAM-negative circulating tumor cells in human and xenograft models of breast cancer
Lang JE, Mineyev N, Ring A, Kahn M, Punj V, Tripathy D, Barsky LW, Zhu W. University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA.
P1-04-08 Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer
Papadaki MA, Agelaki S, Kallergi G, Zafeiriou Z, Theodoropoulos PA, Georgoulias V, Mavroudis D. Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Crete, Greece; University Hospital of Heraklion, Heraklion, Crete, Greece; Laboratory of Biochemistry, School of Medicine, University of Crete, Heraklion, Crete, Greece.
P1-04-09 Extended characterization and target analysis of circulating epithelial cells in early and late breast cancer
Habets L, Bettina F, El-Ghali I, Körber W, Danaei M, Kusche M, Pachmann K. Metares e.V, Aachen, NRW, Germany; Brustzentrum Aachen Kreis Heinsberg, Aachen, NRW, Germany; TZB, Bayreuth, Bavaria, Germany.
P1-04-10 Assessment of circulating tumor cells (CTC) by RT/PCR as a surrogate marker for PFS in metastatic breast cancer (MBC)
Saber MM, Bahnasy AA, El-Zawahry HM, Allahloubi NM, El-Moetii MA, Abd El Fatah RM, Aid S, Ghareeb M. National Cancer Institute, Cairo University, Cairo, Egypt.
P1-04-11 Recovery rates of circulating tumor cells in breast cancer cell lines spiked into peripheral blood
Zhu W, Mineyev N, Ring A, Tripathy D, Punj V, Barsky LW, Lang JE. University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA.
P1-04-12 Prognostic value of CTC detection by RT-PCR and the CellSearch system before first-line chemotherapy in metastatic breast cancer
Agelaki S, Mavroudis D, Politaki E, Apostolaki S, Kallergi G, Spiliotaki M, Georgoulias V. Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Crete, Greece; University Hospital of Heraklion, Heraklion, Crete, Greece.
P1-04-13 The role of excision repair cross-complementation 1 enzyme (ERCC1)-positive circulating tumor cells in primary and metastatic breast cancer
Kasimir-Bauer S, Bredemeier M, Wagner J, Kimmig R, Aktas B. University Hospital of Essen, Essen, Germany; AdnaGen AG, Langenhagen, Germany.
P1-04-14 Role of miR-186 in circulating tumor cells (CTCs)-mediated metastasis in breast cancer
Tucker S, Leong SM, Sufyan M, Chua H, Li M-H, Chang CF, Koay ES-C. Tucker Medical - Singapore, Singapore, Singapore; National University Health System, Singapore, Singapore; National University of Singapore, Singapore, Singapore; CellSievo Private Limited, Singapore, Singapore.
P1-04-15 Breast cancer brain metastasis: Interrogating mechanisms of brain colonization by DEPArray-selected CTC subsets and biomarker discovery
Marchetti D, Zhang L, Ridgway L, Wetzel M, Guerrero P, Goodman J, Yin W, Groves M. Baylor College of Medicine, Houston, TX; Texas Oncology, Austin, TX.
P1-04-16 Multi-center experience with CELLSEARCH® circulating tumor cell kit on patients with metastatic breast cancer
Montero AJ, Eapen S, Tran KN, Gorin B, Adler P. Cleveland Clinic, Cleveland, OH; Analysis Group, Inc., Boston, MA; Janssen Diagnostics, LLC, Raritan, NJ.
  Tumor Cell and Molecular Biology: Mammary Development and Differentiation
P1-05-01 Characterization of human postpartum breast involution: Implications for young women's breast cancer
Borges VF, Jindal S, Gao D, Bell P, Edgerton SM, Ambrosone CB, Thor AD, Schedin P. University of Colorado Denver, Aurora, CO; Rosewell Park Cancer Institute, Buffalo, NY.
P1-05-02 COX-2 expression in normal mammary epithelium is estrogen responsive and predicts expression in DCIS and invasive ductal carcinoma
Schedin P, Fornetti J, Jindal S, Borges V. University of Colorado Anschutz Medical Campus, Aurora, CO.
P1-05-03 Withdrawn
P1-05-04 Withdrawn
P1-05-05 Epithelial cell reprogramming assay reveals inter-individual heterogeneity in stem/basal and progenitor cell profile of the normal breast
Nakshatri H, Anjanappa M, Bhat-Nakshatri P. Indiana University School of Medicine, Indianapolis, IN.
  Tumor Cell and Molecular Biology: Microenvironment / Stromal-Epithelial Interactions
P1-06-01 NSAID use attenuates breast cancer recurrence in obese women: Role of prostaglandin-aromatase interactions
Bowers LW, Maximo IXF, Tekmal RR, Hursting SD, Beeram M, Brenner AJ, deGraffenried LA. University of Texas at Austin; University of Texas Health Science Center at San Antonio; South Texas Accelerated Research Therapeutics, San Antonio, TX. Laura Wells Bowers is a recipient of an AACR Scholar-In-Training Award
P1-06-02 Inflammatory stromal cell response induced by collagen dense stroma is regulated by cyclooxygenase-2 in a mouse breast cancer model
Esbona K, Inman D, Eliceiri K, Wilke LG, Keely PJ. UW-Madison, Madison, WI; Institute for Clinical and Translational Research (ICTR), UW-Madison, Madison, WI; School of Medicine and Public Health, UW-Madison, Madison, WI. Karla Esbona is a recipient of an AACR Scholar-In-Training Award
P1-06-03 Validating the link between obesity and breast inflammation in women with breast cancer (BC)
Iyengar NM, Morris PG, Zhou XK, Giri DD, Harbus MD, Falcone DJ, Gucalp A, Morrow M, Hudis CA, Dannenberg AJ. Memorial Sloan-Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY; Rockefeller University, New York, NY. Neil M. Iyengar is a recipient of an AACR Scholar-In-Training Award
P1-06-04 The predictive value of tumor-stroma ratio for radiological and pathological response to neoadjuvant chemotherapy in breast cancer (BC): A Dutch breast cancer trialists' group (BOOG) side-study
Dekker TJA, Charehbili A, Smit VTHBM, Wasser MNJM, Heijns JB, van Warmerdam LJ, Kessels L, Dercksen W, Pepels M, Maartense E, van Laarhoven HWM, Vriens B, Meershoek-Klein Kranenbarg E, van de Velde CJH, Liefers G-J, Nortier HWR, Tollenaar RAEM, Mesker WE, Kroep JR. Leiden University Medical Center, Leiden, Netherlands; Amphia Hospital, Breda, Netherlands; Catharina Hospital, Eindhoven, Netherlands; Deventer Hospital, Deventer, Netherlands; Maxima Medical Center, Veldhoven, Netherlands; Elkerliek Hospital, Helmond, Netherlands; Reinier de Graaff Gasthuis, Delft, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; Maastricht University Medical Center, Maastricht, Netherlands.
P1-06-05 Expansion of tumor initiating cells is mediated by tumor microenvironment in breast cancer metastasis
Lacerda L, Garza R, Cohen E, Atkinson R, Solley T, Li L, Debeb B, Xu W, Reuben J, Klopp A, Woodward W. The University of Texas MD Anderson Cancer Center, Houston, TX.
P1-06-06 Alteration of stromal collagen fiber orientation in DCIS
Trentham-Dietz A, Conklin MW, Gangnon RE, Sprague BL, Eliceiri KW, Bredfeldt JS, Surachaicharn N, Campagnola PJ, Friedl A, Newcomb PA, Keely PJ. University of Wisconsin Comprehensive Cancer Center, Madison, WI; University of Vermont, Burlington, VT; Fred Hutchinson Cancer Research Center, Seattle, WA.
P1-06-07 Immune-induced epithelial to mesenchymal transition in inflammatory breast cancer induces unique increases in E-cadherin, adhesion and migration through TNF-α, IL-6 and TGF-β
Cohen EN, Gao H, Anfossi S, Giordano A, Tin S, Wu Q, Lee B-N, Luthra R, Krishnamurthy S, Hortobagyi GN, Ueno NT, Woodward WA, Reuben JM. The University of Texas MD Anderson Cancer Center, Houston, TX.
P1-06-08 Arsenic trioxide may block tumor associated macrophage infiltration in estrogen receptor (ER) negative breast cancer and reverse ER status
Ding J, Cao Y, Cui W, Jin W, Shao Z, Wu J. Breast Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China; The Municipal Key Lab of Breast Cancer, The Third Hospital of Nanchang City, Nanchang, Jiangxi, China; Shanghai Medical College, Fudan University, Shanghai, China.
P1-06-09 Engineered model matrix to mimic cancer stem cell microenvironment: Effect of integrin and heparin binding peptides
Jabbari E, Sarvestani SK. University of South Carolina, Columbia, SC.
P1-06-10 Characterization of novel activated human mammary fibroblast lines and their protumorigenic effect on human breast cancer xenotransplants in mice
Peck AR, Yang N, Yanac AF, Utama FE, Jasinski JH, Rosenberg AL, Tanaka T, Rui H. Thomas Jefferson University, Philadelphia, PA.
P1-06-11 Tumor-associated macrophages: CD206 expression and patient outcomes in locally advanced breast cancer
Reynolds JM, Hodges DB, Salam A, Shaw ET, Magoon V, Werlang-Perurena AM, Singh HB, Speights V, Ruud CO, Bhat A. Scott & White Healthcare; Texas A&M Graduate Medical Education, Temple, TX; The University of Texas at Tyler, Tyler, TX; Odyssey Hospice, Austin, TX.
P1-06-12 The therapeutic sensitivity of ER+/Her2+ breast cancer cells is attenuated in 3D matrix culture and involves switching from AKT to MAPK pathways
Gangadhara S, Smith C, Gee J, Nicholson R, Barrett-Lee P, Hiscox S. School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom; Velindre Cancer Centre, Cardiff, Wales, United Kingdom.
P1-06-13 Periostin controls cytokine production to maintain breast cancer stem cells
Lambert AW, Ozturk S, Papageorgis P, Abdolmaleky H, Thiagalingam S. Boston University School of Medicine, Boston, MA; University of Cyprus, Nicosia, Cyprus.
P1-06-14 CCL18 from tumor-associated macrophages promotes breast cancer metastasis via a novel chemokine receptor PITPNM3
Su S, He C, Chen F, Chen J, Song E. Breast Tumor Center, Sun-Yat-Sen Memorial Hospital, Sun-Yat-Sen University, Guangzhou, Guangdong, China
  Tumor Cell and Molecular Biology: Epithelial-Mesenchymal Transition
P1-07-01 Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin
Sabnis GJ, Shah P, Kazi A, Gau Y, Chumsri S, Brodie A. University of Maryland School of Medicine, Baltimore, MD; Loyola University, Baltimore, MD.
P1-07-02 Significance of RB-ZEB axis in EMT phenotype of breast cancer and inhibition of ZEB by CDK4/6 inhibitor
Arima Y, Hosonaga M, Saya H. Institute for Advanced Medical Research, School of Medicine, Keio University, Tokyo, Japan; Tokyo Medical University, Tokyo, Japan.
P1-07-03 Withdrawn
P1-07-04 A novel bioactive approach to inhibit leptin-induced epithelial-mesenchymal transition in breast cancer
Sharma D, Avtanski D, Nagalingam A, Kuppusamy P, Saxena N. Johns Hopkins University, Baltimore, MD; University of Maryland, Baltimore, MD.
P1-07-05 The cell fate factor DACH1 represses YB-1-mediated oncogenic transcription and translation
Pestell RG, Wu K, Chen K, Wang C, Jiao X, Wang J, Cai S, Addya S, Sorensen PH, Lisanti MP, Quong A, Ertel A. Thomas Jefferson University, Philadelphia, PA; British Columbia Cancer Research Center, Vancouer, BC, Canada; University of Manchester, Manchester, England, United Kingdom.
P1-07-06 E2F-1 directly induces HOXB9 accelerating breast cancer progression
Zhussupova A, Hayashida T, Takahashi M, Hiromitsu J, Kitagawa Y. Keio University Hospital, Tokyo, Japan.
P1-07-07 Targeting reversal of epithelial-mesenchymal transition through FOXM1 inhibition in breast cancer cells
Arora R, Tan M, Yates CC, Dean-Colomb W. Mitchell Cancer Institute, University of South Alabama, Mobile, AL; Tuskegee University and Center for Cancer Research, Tuskegee, AL.
P1-07-08 RNA based Twist1 inhibition via dendrimer complex to reduce breast cancer cell metastasis
Finlay JB, Roberts CM, Lowe G, Glackin CA. City of Hope - Beckman Research Institute, Duarte, CA; City of Hope - Irell & Manella Graduate School of Biological Sciences, Duarte, CA.
P1-07-09 The green tea polyphenol EGCG inhibits epithelial to mesenchymal transition (EMT) and stemness in aggressive breast cancer cells and induces tumor regression in mouse xenograft model: Involvement of CCN5
Das A, Banerjee S, De A, Haque I, Maiti G, McEwen M, Banerjee S. VA Medical Center, Kansas City, MO; University of Kansas Medical School, Kansas City, KS.
P1-07-10 HER2 promotes TGFβ/Src mediated epithelial to mesenchymal transition in breast cancer cells
Gupta P, Srivastava SK. TTUHSC, Amarillo, TX.
P1-07-11 ERα regulates epithelial-mesenchymal transition in breast cancers through suppressing Bmi1 expression
Zhang G-J, Wei X, Dou X. The Breast Center, Shantou University Medical College, Shantou, Guangdong, China.
P1-07-12 Kaiso is a novel regulator of epithelial-to-mesenchymal transition in triple negative breast cancer cells
Bassey BI, Crawford C, Daniel JM. McMaster University, Hamilton, ON, Canada.
  Prognosis and Response Prediction: Response Predictive Factors
P1-08-01 MammaPrint ultra-high risk score is associated with response to neoadjuvant chemotherapy in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
Wolf DM, Daemen A, Yau C, Davis S, Boudreau A, Swigart L, I-SPY 1 Trial Investigators, Esserman L, van 't Veer L. University of California, San Francisco; Genentech, San Francisco, CA; I-SPY 1 Trial.
P1-08-02 Chemosensitivity and endocrine sensitivity of MammaPrint and BluePrint in the prospective neo-adjuvant breast registry symphony trial (NBRST)
Whitworth P, Gittleman M, Akbari S, Stork-Sloots L, de Snoo F, Gibson J, Beitsch P. Nashville Breast Center, Nashville, TN; Breast Care Specialists, Allentown, PA; Virginia Hospital Center, Arlington, VA; Agendia NV, Amsterdam, Netherlands; Agendia Inc, Irvine, CA; Dallas Surgical Group, Dallas, TX.
P1-08-03 Prediction of response to neoadjuvant chemotherapy in estrogen receptor positive (ER+) breast cancer by IHC4 or Ki67 alone
Sheri A, Smith IE, A'Hern R, Jones R, Parton M, Johnston SRD, Dowsett M. Royal Marsden Hospital, London, United Kingdom; Institute of Cancer Research, London, United Kingdom; Breakthrough Breast Cancer Centre, Institute of Cancer Research, London; Seattle Cancer Alliance, Seattle, WA.
P1-08-04 The clinical significance of Ki-67 as a marker of chemosensitivity in hormone receptor-positive breast cancer: A meta-analysis of the published literature
Liu Y, Yin W, Yan T, Du Y, Shao Z, Lu J. Shanghai Cancer Hospital/Cancer Institute, Fudan University, Shanghai, China; Shanghai Medical College, Fudan University, Shanghai, China.
P1-08-05 The prognostic significance of Ki-67 expression before and after neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes
Zhang J, Zhang X, Yu F, Liu J, Zhang S, Hao X, Hou G. China Tianjin Breast Cancer Prevention, Treatment and Research Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education; Key Laboratory of Cancer Prevention and Therapy.
P1-08-06 Low tumor CD68 mRNA content (intratumoral macrophages) is predictive for benefit from adjuvant trastuzumab in HER2-positive breast cancer: An analysis of the FinHER trial
Wirtz RM, Leinonen M, Bono P, Isola J, Kellokumpu-Lehtinen P-L, Kataja V, Turpeenniemi-Hujanen T, Jyrkkiö S, Eidt S, Schmidt M, Joensuu H. Stratifyer Molecular Pathology GmbH, Cologne, Germany; Pharma, Turku, Finland; Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland; Institute of Medical Technology, Tampere, Finland; Tampere University Hospital, Tampere, Finland; Kuopio University Hospital, Kuopio, Finland; Oulu University Hospital, Oulu, Finland; Turku University Hospital, Turku, Finland; Institute of Pathology at the St-Elisabeth-Hospital, Cologne, Germany; University Hospital, Mainz, Germany.
P1-08-07 High tumor CD68 mRNA content (intratumoral macrophages) predicts response to neoadjuvant chemotherapy
Wirtz RM, Aigner J, Marme F, Eidt S, Altevogt P, Sinn P, Schneeweiss A. Stratifyer Molecular Pathology GmbH, Cologne, Germany; National Center for Tumor Disease (NCT), Heidelberg, Germany; Institute of Pathology at the St Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Institute of Pathology of the University of Heidelberg, Heidelberg, Germany.
P1-08-08 Tumor infiltrating lymphocytes (TILs) in breast cancer: A meta-analysis of response to neoadjuvant chemotherapy based on TIL status
Janakiram M, Zhang L, White R, Ayyappan S, Sparano J. Albert Einstein College of Medicine, Bronx, NY; Montefiore Medical Center, Bronx, NY; Case Western Reserve University, Cleveland, OH. Murali Janakiram is a recipient of an SABCS Clinical Scholars scholarship
P1-08-09 EGFR expression is associated with decreased response from HER2 targeted therapeutics in the neo-adjuvant setting in the NeoALTTO trial
Rimm DL, Holmes E, Schalper K, Bradbury I, Zarrella E, Ellis C, Baselga J, Eidtmann H, Piccart M, Harbeck N, Pusztai L, Perez E. Yale University School of Medicine, New Haven, CT; Frontier Science, Scotland, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Christian Albrechts University of Kiel, Keil, Germany; Jules Bordet Institute, Brussels, Belgium; University of Munich, Munich, Germany; Mayo Clinic, Jacksonville, FL; Glaxo Smith Kline.
P1-08-10 Integration of next generation sequencing (NGS) and patient derived xenografts (PDX) to identify novel markers of paclitaxel (T) response in the breast cancer genome guided therapy study (BEAUTY)
Goetz MP, Boughey JC, Kalari KR, Eckel-Passow J, Suman VJ, Sicotte H, Hart SN, Moyer AM, Visscher DW, Yu J, Gao B, Sinnwell JP, Mahoney DW, Barman P, Vedell P, Tang X, Thompson K, Dockter TJ, Jones KN, Conners AL, McLaughlin SA, Moreno-Aspitia A, Northfelt DW, Gray RJ, Wieben ED, Farrugia G, Schultz C, Ingle JN, Wang L, Weinshilboum RW. Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ.
P1-08-11 Association of variants in candidate genes on lipid profiles in women with early breast cancer on adjuvant aromatase inhibitor therapy
Santa-Maria CA, Dantzer J, Li L, Skaar T, Oesterreich S, Rae JM, Zeruesenay D, Nguyen AT, Henry NL, Storniolo AM, Hayes DF, Blumenthal RS, Ouyang P, Post W, Flockhart DA, Stearns V. Johns Hopkins Sidney Kimmel Comprehensive Cancer Center; Indiana University School of Medicine; University of Pittsburgh Cancer Institute; University of Michigan Comprehensive Cancer Center; Johns Hopkins University School of Medicine. Cesar Augusto Santa-Maria is a recipient of an AACR Scholar-In-Training Award
P1-08-12 G protein-coupled estrogen receptor in the plasma membrane is prognostic in early breast cancer
Sjöström M, Hartman L, Fornander T, Grabau D, Malmström P, Nordenskjöld B, Skoog L, Stĺl O, Leeb-Lundberg F, Fernö M. Clinical Sciences, Lund University, Lund, Sweden; Karolinska Institute, Stockholm, Sweden; Skĺne University Hospital, Lund, Sweden; Linköping University, Linköping, Sweden; Drug Target Discovery, Experimental Medical Scence, Lund University, Lund, Sweden; Lund University, Lund, Sweden.
P1-08-13 Predictive value of intrinsic luminal subtypes in premenopausal women with endocrine-responsive early breast cancer: Results from Austrian breast and colorectal cancer study group trial 5
Bago-Horvath Z, Rudas M, Jakesz R, Greil R, Dietze O, Suppan C, Lax S, Singer CF, Filipits M, Gnant M. Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Medical University of Vienna, Vienna, Austria; Paracelsus Private Medical University, Salzburg, Austria; Medical University of Graz, Graz, Austria; General Hospital Graz West, Graz, Austria.
P1-08-14 HER2 extracellular domain (ECD): A predictive marker of lapatinib treatment benefit in advanced breast cancer
Lee CK, Davies L, Gebski V, Lord S, Di Leo A, Johnston S, Geyer, Jr C, Cameron D, Press M, Ellis C, Simes J, deSouza P. NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia; Hospital of Prato, Prato, Italy; The Royal Marsden NHS Foundation Trust, London, United Kingdom; Virginia Commonwealth University Massey Cancer Center, Richmond, VA; The University of Edinburgh, United Kingdom; The University of Southern California, Norris Comprehensive Cancer Center; GlaxoSmithKline; University of Western Sydney, Australia.
P1-08-15 Prognostic value of five different histologic scoring systems for tumor regression after neoadjuvant chemotherapy of breast cancer in luminal type breast cancer
Sinn P, Elsawaf Z, Kaip G, Heil J, Aulmann S, Marmé F, Schneeweiss A. University of Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, Heidelberg.
P1-08-16 Deep sequencing of breast tumor biopsies reveals an association between pathologic complete response and reduction of TP53 clonal abundance upon brief exposure to therapy
Williams N, Varadan V, Miskimen K, Vadodkar A, Poruban D, Edelheit S, Gilmore H, Maximuk S, Sinclair N, Lezon-Geyda K, Abu-Khalaf M, Sikov W, Harris L. University Hospitals/Case Medical Center, Cleveland, OH; Yale University School of Medicine; Yale Comprehensive Cancer Center, New Haven, CT; Warren Alpert Medical School of Brown, Providence, RI.
P1-08-17 Impact of claudin-3 and basal-markers expressions on pathological complete response to neoadjuvant chemotherapy and prognosis in triple negative breast cancer
Nogi H, Kamio M, Kato K, Toriumi Y, Suzuki M, Uchida K, Takeyama H. Jikei University School of Medicine, Minato-ku, Tokyo, Japan.
P1-08-18 PIK/AKT/MTOR pathway activation in triple negative breast cancer and outcomes with matched therapy in phase I clinical trials: Response in both patients with and without direct molecular alterations
Ganesan P, Moulder S, Janku F, Naing A, Fu S, Tsimberidou AM, Hong DD, Stephens P, Yelensky R, Meric F, Kurzrock R, Wheler JJ. UT MD Anderson Cancer Center, Houston, TX; Foundation Medicine, Cambridge, MA; Univ. of California, San Diego, Moores Cancer Center, La Jolla, CA.
P1-08-19 Changes in circulating vitamin D levels as a predictor for pathological response to neoadjuvant chemotherapy (NAC) in breast cancer (BC): A Dutch breast cancer trialists group (BOOG) side-study
Charehbili A, Hamdy NAT, Smit VTHBM, Liefers G-J, Putter H, Meershoek-Klein Kranenbarg E, Heijns JB, van Warmerdam LJ, Kessels LW, Dercksen W, Pepels MJ, Maartense E, van Laarhoven HWM, Vriens B, van Leeuwen-stok E, van de Velde CJH, Nortier HWR, Kroep JR. Leiden University Medical Center, Leiden, Netherlands; Amphia Hospital, Breda, Netherlands; Catharina Hospital, Eindhoven, Netherlands; Deventer Hospital, Deventer, Netherlands; Maxima Medical Center, Veldhoven, Netherlands; Elkerliek Hospital, Helmond, Netherlands; Reinier de Graaf Gasthuis, Delft, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; Maastricht University Medical Center, Maastricht, Netherlands; BOOG; Dutch Breast Cancer Trialists' Group, Amsterdam, Netherlands.
P1-08-20 Increased risk of hormone therapy failure in breast cancers expressing low phospho-Stat5: Validation of quantitative immunofluorescence assay parameters
Girondo MA, Peck AR, Freydin B, Chervoneva I, Hyslop T, Kovatich AJ, Hooke JA, Shriver CD, Mitchell EP, Rui H. Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; MDR Global Systems, LLC, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD.
P1-08-21 Detection and monitoring of circulating endothelial cells, circulating tumor cells and disseminated tumor cells during neoadjuvant breast cancer treatment including bevacizumab
Mathiesen RR, Borgen E, Sćtersdal AB, Fangberget A, Schirmer C, Stav I, Fagerland MW, Wist E, Engebrĺten O, Naume B. Oslo University Hospital, Oslo, Norway; Oslo University Hospital, The Radium Hospital, Oslo, Norway; Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Oslo University Hospital Ullevĺl, Oslo, Norway; Institute for Clinical Medicine, University of Oslo, Oslo, Norway.
P1-08-22 The impact of obesity on response to neoadjuvant chemotherapy in operable breast cancer patients
Lee HY, Jung SP, Kim S, Kim HY, Bae JW, Lee JB. Korea University Hospital, Korea University College of Medicine, Seoul, Korea.
P1-08-23 Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer
Montemurro F, Prat A, Rossi V, Valabrega G, Sperinde J, Peraldo-Neia C, Donadio M, Galvan P, Sapino A, Aglietta M, Baselga J, Scaltriti M. Fondazione del Piemonte per l'Oncologia/IRCCCandiolo; Vall d'Hebron Institute of Oncology (VHIO); Monogram Biosciences; A.O. Cittŕ della Salute e della Scienza di Torino; Universitŕ di Torino; Memorial Sloan Kettering Cancer Center.
P1-08-24 High tumor RNA disruption is associated with increased survival in patients with locally advanced breast cancer
Parissenti AM, Guo B, Pritzker L, Pritzker K, Wang X, Zhu M, Trudeau ME. Advanced Medical Research Institute of Canada, Sudbury, ON, Canada; RNA Diagnostics, Inc., Toronto, ON, Canada; Odette Cancer Centre, Toronto, ON, Canada; University of Waterloo, Waterloo, ON, Canada; Laurentian University, Sudbury, ON, Canada.
P1-08-25 RANK expression is prognostic and predictive in primary breast carcinoma: Analysis of samples from the GeparTrio study
Pfitzner BM, Branstetter D, Mergler B, Loibl S, Denkert C, Fasching PA, Dougall WC, von Minckwitz G. Charite, Berlin, Germany; Amgen Inc., Seattle, WA; German Breast Group, Neu-Isenburg, Germany; University Hospital Erlangen, Friedrich Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany; Therapeutic Innovation Unit, Amgen Inc., Seattle, WA; University Women's Hospital Frankfurt, Frankfurt, Germany.
P1-08-26 Hypertension and phosphorylated vascular endothelial growth factor receptor 2 are potential independent predictive factors for progession-free survival in apatinib-treated advanced breast cancer
Fan M, Hu X, Zhang J, Wang Z, Zhang Q. Fudan University Shanghai Cancer Center, Shanghai, China. Minhao Fan is a recipient of an Avon-AACR International Scholar-In-Training Award
P1-08-27 Quantitative analysis of tumor expression of phosphoproteins from PI3-kinase and MAP-kinase signaling pathways as biomarkers of the biological and clinical activity of trastuzumab and everolimus in breast cancer: Unicancer RADHER phase II trial results
Merlin J-L, Lion M, Wong J, Bachelot T, André F, Treilleux I, Loussouarn D, Bonneterre J, Rios M, Diéras V, Jimenez M, Leroux A, Campone M. Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France.
P1-08-28 Withdrawn
P1-08-29 Withdrawn
P1-08-30 Identification of plasma protein biomarkers of radiation response in breast cancer
Quong AA, Gormley M, Zellars R. Thomas Jefferson University, Philadelphia, PA; Johns Hopkins University, Baltimore, MD.
P1-08-31 Putative role of genetic variants of eNOS in survival and toxicity of patients given antiangiogenic therapy
Del Re M, Fontana A, Del Re I, Bona E, Salvadori B, Ferrarini I, Landucci E, Fancelli S, Bertolini I, Michelotti A, Falcone A, Danesi R. University of Pisa, Pisa, Italy; Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
P1-08-32 Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer
Gampenrieder SP, Hufnagl C, Brechelmacher S, Huemer F, Hackl H, Rinnerthaler G, Romeder F, Muß C, Pircher M, Ressler S, Kronberger C, Mlineritsch B, Greil R. Oncologic Center, Laboratory of Immunological and Molecular Cancer Research, Paracelsus Medical University Salzburg, Salzburg, Austria; Biocenter, Innsbruck Medical University, Innsbruck, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria.
P1-08-33 Withdrawn
P1-08-34 Is it possible to predict the efficacy of a combination of cetuximab plus docetaxel in patients with operable, triple negative breast cancer (TNBC)? Final biomarker results from a phase II neoadjuvant trial
Nabholtz J-M, Mouret-Reynier M-A, Abrial C, Dauplat M-M, Radosevic-Robin N, Van Praagh I, Servent V, Jacquin J-P, Bourcier A-V, Del Piano F, Dubray-Longeras P, Nayl B, Kwiatkoswki F, Cayre A, Uhrhammer N, Bidet Y, Chalabi N, Bignon Y-J, Chollet P, Penault-Llorca F. Jean Perrin Comprehensive Cancer and ERTICA EA 4677 Research Team, University of Auvergne, Clermont-Ferrand, France; Oscar Lambret Comprehensive Cancer Centre, Lille, France; Lucien Neuwirth Institute, Saint-Etienne, France; General Hospital, La Roche sur Yon, France; Georges Pianta Hospital, Thonon, France; Pole Santé République, Clermont-Ferrand, France; Jean Perrin Comprehensive Cancer Centre, INSERM UMR990, University of Auvergne, Clermont-Ferrand, France.
P1-08-35 Androgen receptor expression and changes in serum dehydroepiandrosterone sulfate levels in locally advanced breast cancer patients who received neoadjuvant chemotherapy
Park S, Lee JS, Park JM, Park HS, Kim SI, Park B-W. Yonsei University College of Medicine, Seoul, Korea.
P1-08-36 Neoadjuvant trial of bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: A phase II trial (AVANTHER). Analysis of biomarkers
Fernández M, Martinez N, Calvo I, Garcia E, Ugidos L, Herrero M, Quijano Y, Durán H, Garcia M, Suarez A, López-Rios F, Perez D, Perea S, Hidalgo M, Garcia-Estevez L. Centro Integral Oncológico Clara Campal, Madrid, Spain; Hospital Ramón y Cajal, Madrid, Spain; Centro Nacional de Investigaciones Oncológicas, Madrid, Spain; Hospital Costa del Sol, Marbella, Malaga, Spain.
P1-08-37 Magee equations predict pathologic response to neoadjuvant chemotherapy
Skinner KA, Farkas RL, Shayne M, Huston A, Peacock JL, Bell LA, Turner BM, Jackson MC, Tang P, Hicks DG. University of Rochester Medical Center, James P Wilmot Cancer Center, Rochester, NY.
P1-08-38 HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-postive metastatic breast cancer
Lee HJ, Seo AN, Kim EJ, Jang MH, Suh KJ, Ryu HS, Kim YJ, Kim JH, Im S-A, Gong G, Park IA, Jung KH, Park SY. Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea; Seoul National University Bundang Hospital; Seoul National University Hospital; Seoul National University College of Medicine; Asan Medical Center, University of Ulsan College of Medicine.
P1-08-39 Tumor-infiltrating CD8+ lymphocytes as an independent predictive factor for pathologic complete response to primary systemic therapy in breast cancer
Seo AN, Lee HJ, Kim EJ, Kim HJ, Lee HE, Kim YJ, Kim JH, Park SY. Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Republic of Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Seoul National University College of Medicine, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Gyeonggi, Republic of Korea.
P1-08-40 BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refrectory to taxane-based neoadjuvant chemotherapy
Foedermayr M, Sebesta M, Rudas M, Berghoff AS, Promberger R, Preusser M, Dubsky P, Fitzal F, Gnant M, Steger GG, Weltermann A, Zielinski CC, Zach O, Bartsch R. Academic Teaching Hospital Elisabethinen Linz, Linz, Austria; Medical University of Vienna, Vienna, Austria.
P1-08-41 Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near infrared imaging and tumor pathologic criteria
Zhu Q, Wang L, Tannenbaum S, Ricci, Jr A, DeFusco P, Hegde P. University of Connecticut, Storrs, CT; University of Manitoba, Winnipeg, MB, Canada; University of Connecticut Health Center, Farmington, CT; Hartford Hospital, Hartford, CT.
P1-08-42 High HER2 expression correlates with response to trastuzumab and the combination of trastuzumab and lapatinib in the NeoALTTO phase III trial
Scaltriti M, Nuciforo P, Bradbury I, Sperinde J, Serra V, Parra JL, Prudkin L, Harbeck N, Pusztai L, Ellis C, Eidtmann H, Arribas J, Piccart M, Baselga J. Memorial Sloan Kettering Cancer Center; Vall d'Hebron Institute of Oncology; Frontier Science Scotland; Monogram Biosciences; Ludwig Maximilian University; Yale School of Medicine; GlaxoSmithKline; University Hospital Kiel; Jules Bordet Institute.
  Psychosocial, Quality of Life, and Educational Aspects: Disparities and Barriers to Care
P1-09-01 The effect of generic anastrozole on adherence to adjuvant endocrine therapy
Neuner JM, Kamaraju S, Smith E, Charlson J, Smallwood A, Laud P, Pezzin L. Medical College of Wisconsin, Milwaukee, WI.
P1-09-02 GIS exploration: Might triple negative breast cancer patients face disparities in access to clinical trials due to distance?
Vollmer Dahlke D, Cohen E, Seago-Coyle R. TX A&M School for Rural Public Health, College Station, TX; UCSF, San Francisco, CA.
P1-09-03 The use of MRI in the evaluation of breast cancer
Washington TM, Sharma G, Zhang W, Cooksley C. The University of Texas Medical Branch, Galveston, TX.
P1-09-04 Use of adjuvant chemotherapy and outcomes in women 70 years and older with HER-2 positive or triple negative breast cancer
Hsu T, Speers C, Tyldesley S, Mcgahan C, Chia SK. British Columbia Cancer Centre, Vancouver, BC, Canada.
P1-09-05 Does socioeconomic status (SES) influence receipt of guideline concordant care in older women with breast cancer: Findings from a Centers for Disease Control and Prevention national program of cancer registries (NPCR) patterns of care study
Ursem C, Fleming ST, Sabatino S, Wu X-C, Wilson JF, Lipscomb J, Cress R, Anderson R, Kimmick G. Duke University Medical Center, Durham, NC; University of Kentucky College of Public Health, Lexington, KY; Louisiana State University Health Sciences Center, New Orleans, LA; Rollins School of Public Health, Atlanta, GA; Centers for Disease Control and Prevention, Atlanta, GA; Medical College of Wisconsin, Milwaukee, WI; UC Davis School of Medicine, Sacramento, CA; Penn State College of Medicine, Hershey, PA.
P1-09-06 Breast cancer in the Pan-American region: Inequities in incidence and mortality rates according to the human development index
Barrios CH, Werutsky G, Martínez-Mesa J. Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil.
P1-09-07 Withdrawn
P1-09-08 Breast cancer (BC) outcomes after implementation of "Seguro popular" at the National Institute of Medical Sciences and Nutrition, Salvador Zubiran (INCMNSZ) in Mexico
Castro Sánchez A, Meneses Medina MI, Chávarri Guerra Y, Pérez Álvarez SI, León Rodríguez E, Armengol Alonso A. Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico. Andrea Castro Sánchez is a recipient of an Avon-AACR International Scholar-In-Training Award
P1-09-09 Breast cancer reporting in Lagos, implications for training and education in Africa
Daramola AO, Banjo AF, Abdulkareem FB, Shaaban AM. Lagos University Teaching Hospital, Surulere, Lagos, Nigeria; St James's University Hospital, Leeds, United Kingdom.
P1-09-10 Disparities in presentation of breast cancer in a geriatric population
Ursem C, Camacho F, Anderson R, Kimmick G. Duke University Medical Center, Durham, NC; Penn State College of Medicine, Hershey, PA.
P1-09-11 Can patient navigation help overcome barriers to breast cancer treatment in patients with health care disparities?
Elrafei T, Castaldi M, Shaker A, Stanise T, Gralla R, Matquez M, Bodner W, Reed L, Strakhan M, Alexis K. Jacobi Medical Center, Bronx, NY; Albert Einstein College of Medicine, Bronx, NY; Montefiore Medical Center, Bronx, NY.
P1-09-12 The interplay of biologic factors, race, and delivery of care in improving breast cancer outcomes
Weber JJ, Kachare SD, Vohra NA, Fitzgerald TF, Wong JH. East Carolina University, Brody School of Medicine, Greenville, NC; Leo Jenkins Cancer Center, East Carolina University, Greenville, NC; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC.
P1-09-13 Ethnically diverse population of low and high-risk women lack provider education regarding personal breast cancer risk
Herman SM, Herman JD, Pachtman S, Indelicato J, Daus D. Stella K. Abraham, Hewlett, NY; Hofstra North Shore-LIJ Medical School, New Hyde Park, NY; Touro School of Behavioral Science, Islip, NY.
P1-09-14 Relationship between socioeconomic status, race, and breast cancer clinical stage at presentation
Wray CJ, Nguyen BC, Wiatrek RL, Robinson EK, Ko TC, Kao LS. University of Texas Medical School at Houston, Houston, TX.
P1-09-15 Perception of breast cancer risk in an underinsured safety net population
Komenaka IK, Wikholm L, Hsu C-H, Wells K, Bouton ME, Thompson PA, Schwab R, Nodora J, Martinez ME. Maricopa Medical Center, Phoenix, AZ; University of Arizona, Tucson, AZ; University of California San Diego, San Diego, CA.
P1-09-16 Factors affecting disparities in advanced stage breast cancer
Samiian L, Kraemer D, Butterfield R, Osian SR, Lukens-Bull K, Wood D. University of Florida College of Medicine, Jacksonville, FL; Department of Health, Jacksonville, FL.
P1-09-17 Breast cancer stage at presentation not dependent upon primary care provider proximity or type in central North Dakota
Dufan T, Watkins J, Watkins P. Bismarck Cancer Center, Bismarck, ND; University of North Dakota School of Medicine and Health Sciences, Bismarck, ND.
P1-09-18 Doctors with breast cancer are more likely to opt for mastectomy: Fact or fiction?
O'Connell RL, Gui G, Rusby JE. The Royal Marsden Hospital, London, United Kingdom.
P1-09-19 Demographic trends in clinical trial withdrawal rate within the bubble study
Riley EC, Jain D, Kantardzic B, Wu X, Rai SN. James Graham Brown Cancer Center, University of Louisville, Louisville, KY.
P1-09-20 Patient navigation significantly improves vulnerability score after breast cancer. A pilot experience in an underprivileged community
Zelek L, Festa A, Morin N, Bodere C, Morere J-F, Boubaya M, Levy V. Assistance Publique Hôpitaux de Paris, CHU Avicenne, Bobigny, France; Oncologie 93, Bobigny, France.
P1-09-21 Impact of the benfluorex scandal on French cancer patients' attitude toward clinical trials
Hajjaji N. University Hospital of Tours, Tours, France.
P1-09-22 Withdrawn
P1-09-23 Disparities in female breast cancer mortality rates between urban centers and rural areas of Brazil: Ecological time series study
Freitas-Junior R, Gonzaga CMR, Souza MR, Curado M-P, Freitas NMA. Federal University of Goias, Goiania, Goias, Brazil; International Prevention Research Institute, Espace Europeen, Ecully, France; Araujo Horge Hospital, Goias Anticancer Association, Goiania, Goias, Brazil.
  Psychosocial, Quality of Life, and Educational Aspects: Advocacy
P1-10-01 Patient advocate involvement shapes UK's first national breast cancer tissue bank - The breast cancer campaign tissue bank
Morgan A, Gath J, MacKenzie M, Matthews A, Stobart H, Turner L, Wilcox M. Independent Cancer Patients' Voice, United Kingdom.
P1-10-02 YSC research think tank to determine top priority research needs in young breast cancer patients
Esser M, Lewis S, Rowe J, McCann M, Singh N. Young Survival Coalition, New York, NY.
P1-10-03 Male breast cancer: Opportunities for increased research funding and clinical trial access
Bogler O. UT MD Anderson Cancer Center, Houston, TX.
  Psychosocial, Quality of Life, and Educational Aspects: Doctor-Patient Communication
P1-11-01 eHealth in modern patient-caregiver-communication: High rate of modern media use in physicians as well as breast cancer patients
Wuerstlein R, Kirkovits T, Drewes C, Bauerfeind I, Goldmann-Posch U, Roedder P, Peine A-C, Schiltz D, Harbeck N, Schinkoethe T. University Hospital Munich, Breast Center, Muenchen, Germany; TZM, Breast Group, Landshut, Germany; Mamazone, Augsburg, Germany.
P1-11-02 Identifying women at high-risk for breast cancer in the primary care setting
Crew KD, Sivasubramanian PS, Aguirre AN, Smalletz C, Ngan MC, Xiao T, Kukafka R. Columbia University Medical Center, New York, NY.
P1-11-03 Breast cancer trial design may influence recruitment to RCTs
Jenkins VA, Fallowfield LJ. BSMS, University of Sussex, Brighton, East Sussex, United Kingdom.
  Psychosocial, Quality of Life, and Educational Aspects: Education
P1-12-01 Clinical impact of internet-based tools to help guide therapeutic decisions for metastatic breast cancer (MBC)
Obholz KL, Blackwell KL, Glück S, Jahanzeb M, Miller KD, Robert NJ, Bowser AD, Mortimer J, Carlson RW. Clinical Care Options, LLC, Reston, VA; Duke Cancer Institute, Durham, NC; University of Miami, Miami, FL; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Virginia Cancer Specialists, Fairfax, VA; National Comprehensive Cancer Network, Fort Washington, PA.
P1-12-02 Predictive variables of additional contacts with breast cancer counselors after sentinel lymph node negative breast conserving surgery in postmenopausal women
Vandezande L, Reymen M, Raeymaekers B, Neven P, Christiaens M-R. KU Leuven, University Hospitals Nursing Center of Excellence, Leuven, Belgium; KU Leuven, University Hospitals Multidisciplinary Breast Center, Leuven, Belgium.
P1-12-03 Primary squamous cell carcinoma of the breast
Lee ES, Lundberg TM, Ley MB, Waer A, Livingston RB, Stopeck AT, Chalasani P, Gonzalez VJ, LeBeau LG, Rose JF, Viscusi RK. University of Arizona Health Network, Tucson, AZ.
  Treatment: Adjuvant Endocrine Therapy
P1-13-01 Risk of recurrence following 5 years of adjuvant hormone therapy for hormone receptor positive early breast cancer
Lohrisch C, Speers C, Chia S, Kennecke H, Ellard S, Tyldesley S. BC Cancer Agency, Vancouver Centre, Vancouver, BC, Canada; BC Cancer Agency, Centre for the Southern Interior, Kelowna, BC, Canada.
P1-13-02 Benefit/risk of invasive breast cancer adjuvant tamoxifen or aromatase inhibitor use by age, race/ethnicity, and co-morbidity
Chlebowski RT, Haque R, Col N, Paskett E, Manson JE, Kubo JT, Johnson KC, Wactawski-Wende J, Anderson G. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Kaiser Foundation Research Institute, Pasadena, CA; University of New England, Portland, ME; Ohio State University, Columbus, OH; Harvard Medical School, Boston, MA; Stanford School of Medicine, Palo Alto, CA; University of Tennessee, Memphis, TN; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA.
P1-13-03 ER, PR, HER2, and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial
Knoop AS, Lćnkholm A-V, Jensen M-B, Nielsen KV, Andersen J, Nielsen D, Ejlertsen B. Rigshospitalet, Copenhagen, Denmark; Slagelse Hospital, Slagelse, Denmark; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Dako Denmark A/S, Glostrup, Denmark; Aarhus University Hospital, Aarhus, Denmark; Herlev University Hospital, Herlev, Denmark; Department of Oncology, Odense, Denmark.
P1-13-04 A comparison of cardiovascular outcomes in postmenopausal women treated with aromatase inhibitors versus tamoxifen in breast cancer
Fiorino LH, Pitz M. University of Manitoba, Winnipeg, MB, Canada.
P1-13-05 A prospective study to evaluate joint changes by ultrasound and magnetic resonance imaging induced by adjuvant chemotherapy followed by aromatase inhibitors in postmenopausal early breast cancer patients developing G3 arthralgia
Fontaine C, Shahabpour M, Decoster L, Hanssens S, Schallier D, Boulet C, Vanhoeij M, Verfaillie G, Lamote J, De Grčve J. UZ Brussels, Jette, Brussels, Belgium.
P1-13-06 Correlation between aromatase-induced arthralgia and inflammatory cytokines in postmenopausal patients with early breast cancer treated with surgery followed by adjuvant hormone therapy: A prospective open-label single center study
Fontaine C, Decoster L, Njemini R, Hanssens S, Fils J-F, Schallier D, Vanhoeij M, Verfaillie G, Lamote J, De Grčve J. UZ Brussel, Jette, Vlaams Brabant, Belgium.
P1-13-07 Chemotherapy, but not body mass index has impact on joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: A prospective multicenter cohort study of patient-reported outcomes
Hirokaga K, Egawa C, Takao S, Yamagami K, Miyashita M, Baba M, Ichii S, Konishi M, Kikawa Y, Minohata J, Okuno T, Miyauchi K, Wakita K, Suwa H, Hashimoto T, Nishino M, Matsumoto T, Yoshida M, Konishi Y, Miyoshi Y. Hyogo Cancer Center, Akashi, Japan; Kansai Rosai Hospital, Amagasaki, Japan; Shinko Hospital, Kobe, Japan; Kohnan Hospital, Kobe, Japan; Itami City Hospital, Itami, Japan; Rokko Island Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan; Kobe City Hospital Organization Kobe City Medical Center West Hospital, Kobe, Japan; Kobe-Kyodo Hospital, Kobe, Japan; Nishikobe Medical Center, Kobe, Japan; Miyauchi Clinic, Amagasaki, Japan; Chayamachi Breast Clinic, Osaka, Japan; Hyogo Prefectural Tsukaguchi Hospital, Amagasaki, Japan; Hashimoto Clinic, Kobe, Japan; Takarazuka City Hospital, Takarazuka, Japan; Kinki Central Hospital, Itami, Japan; Kobe Century Memorial Hospital, Kobe, Japan; Kobe Urban Breast Clinic, Kobe, Japan; Hyogo College of Medicine, Nishinomiya, Japan.
P1-13-08 Arthralgia and changes in serum levels of IGF-I, its binding protein and estrogen in breast cancer patients on endocrine agents
Lintermans A, Van Asten K, Wildiers H, Paridaens R, Leunen K, Smeets A, Amant F, Christiaens M-R, Verhaeghe J, Vermeersch P, Vanderschueren D, Neven P. KU Leuven, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium.
P1-13-09 Sensitive liquid chromatography-tandem mass spectrometry method for serum estradiol and estrone assessment without derivatisation, overcoming cross reactivity with exemestane
Lintermans A, Pauwels S, Vermeersch P, Jans I, Billen J, Van Asten K, Vanderschueren D, Neven P. KU Leuven, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium.
P1-13-10 Long-term pathologic findings in the female genital tract after completion of tamoxifen therapy for premenopausal breast cancer
Illarramendi JJ, Laplaza Y, Guarch R, Salgado E, Muruzabal JC, Garcia Bragado F, Aguirre S, De La Cruz S, Lainez N, Vera R. Complejo Hospitalario de Navarra, Pamplona, Spain.
P1-13-11 Supervising circulating tumor cells during and beyond maintenance therapy with SERM or aromatase inhibitors. A way to better support our patients to make decisions in long-term survivorship
Pachmann K, Rabenstein C, Camara O, Ingo RB, Ulrich P. Transfusion Center, Bayreuth, Germany; Hufeland Klinikum, Bad Landensalza, Germany; Women's Hospital University Hospital, Jena, Germany.
P1-13-12 Intermittent letrozole as adjuvant treatment in postmenopausal hormone-receptor positive early breast cancer patients
Balduzzi A, Bagnardi V, Volpe S, Cancello G, Iorfida M, Dellapasqua S, Sandri M, Goldhirsch A, Colleoni M. European Institute of Oncology, Milan, Italy; European Institute of Oncology.
P1-13-13 Association between the serum concentrations of tamoxifen and its metabolites and age during steady state breast cancer treatment
Lien E, Sřiland H, Lundgren S, Ĺs T, Steen VM, Mellgren G, Gjerde J. Clinical Inst 2, Bergen, Norway; Cancer Clinic, Trondheim, Norway; Stavanger University Hospital, Stavanger, Norway; Haukeland University Hospital, Bergen, Norway.
P1-13-14 Discordance of ER and PR status between primary and recurrent breast cancer in association with endocrine therapy
Menjak IB, Maki E, Chung C, Berman HK, McCready DR, Sridhar SS. Princess Margaret Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Analytica Statistical Consulting, Toronto, ON, Canada.
P1-13-15 Risk of late recurrence of hormone receptor positive breast cancer in cases with no recurrent disease at five years after surgery
Ohno S, Koui Y, Oikawa M, Akiyoshi S, Koga C, Igawa A, Saruwatari A, Nishimura S, Nakamura Y, Taguchi K, Ishida M. Clinical Research Center, National Kyushu Cancer Center, Fukuoka, Japan; National Kyushu Cancer Center, Fukuoka, Japan.
P1-13-16 Women commencing with anastrozole, letrozole or tamoxifen: The impact of comorbidity and demographics on initial choice
Boyle F, Kemp A, Preen DB, Saunders C, Bulsara M, Malacova E, Roughead EE. The Mater Hospital, Sydney, New South Wales, Australia; The University of Western Australia, Perth, Western Australia, Australia; University of Notre Dame, Perth, Western Australia, Australia; University of South Australia, Adelaide, South Australia, Australia.
  Treatment: Advanced Endocrine Therapy
P1-14-01 Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior non-steroidal aromatase inhibitor treatment in postmenopausal women with hormone receptor-positive metastatic breast cancer (Hi-FAIR ex study)
Yamamoto Y, Ishikawa T, Hozumi Y, Ikeda M, Kondo N, Yamashita H, Toyama T, Takashi C, Saji S, Yamamoto-Ibusuki M, Iwase H. Kumamoto University Hospital, Kumamoto, Japan; Yokohama City University Medical Center, Yokohama, Japan; Jichi Medical University Hospital, Shimotsuke, Japan; Fukuyama City Hospital, Fukuyama, Japan; Aichi Cancer Center Hospital, Aichi, Japan; Hokkaido University Hospital, Sapporo, Japan; Nagoya City University, Nagoya, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Kyoto University Graduate School of Medicine, Kyoto, Japan; Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan.
P1-14-02 Reversing endocrine resistance: A pilot study of estradiol followed by exemestane
Chalasani P, Stopeck A, Clarke K, Livingston RB. University of Arizona Cancer Center, Tucson, AZ.
P1-14-03 Chemotherapy and endocrine therapy treatment patterns among patients with hormone receptor positive (HR+)/HER2 negative advanced breast cancer
Hao Y, Engel-Nitz NM, Sullivan J, Henk HJ, Willemann Rogerio J, Newcomer L. Novartis Pharmaceuticals Corporation, East Hanover, NJ; OptumInsight, Eden Prairie, MN; Allina Health, Formerly Employed by OptumInsight, Minneapolis, MN; UnitedHealthcare, Minnetonka, MN.
P1-14-04 Subsequent endocrine therapy after becoming to resistance of ‘estrogen therapy' is beneficial as a salvage treatment for the late stage metastatic breast cancer
Iwase H, Yamamoto Y, Yamamoto-Ibusuki M, Murakami K-I, Inao T, Okumura Y, Omoto Y. Kumamoto University, Kumamoto, Japan.
P1-14-05 Is there a correlation between androgen receptor (AR) expression in metastatic breast cancer (MBC) ER+/Her2- and response to anti-estrogen treatment?
Riesco Martínez MC, Hanna W, Ghorab Z, Warner E. Sunnybrook Odette Cancer Centre, Toronto, ON, Canada.
P1-14-06 Everolimus effect on hematologic parameters in a phase II clinical trial for metastatic estrogen receptor (ER) positive breast cancer
Chen A, Chen L, Romond E, Kadamyan V, Stevens M, Chambers M, Massarweh S. University of Kentucky and Markey Cancer Center, Lexington, KY.
  Treatment: Neoadjuvant Endocrine Therapy
P1-15-01 A randomized phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally-advanced hormone-receptor-positive breast cancer: First results
Quenel-Tueux N, Dalenc F, Bachelot T, Pulido M, Bonnefoi H, Mauriac L, Madranges N, Iggo R, Lortal B, Tunon de Lara C, Campo P, Debled M. Institut Bergonie, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Leon Berard, Lyon, France.
P1-15-02 Long term follow-up of the neo-adjuvant pilot trial evaluating activity of letrozole in combination with bevacizumab in post-menopausal women with newly diagnosed estrogen and/or progesterone receptor positive primary breast cancer
Forero A, DeLos Santos J, Bowen K, Jones C, Varley K, Nabell L, Carpenter JT, Falkson CI, Krontiras H, Caterinicchia V, O'Malley J, Li Y, LoBuglio AF, Myers R, Saleh MN. University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA; HudsonAlpha Institute for Biotechnology, Huntsville, AL.
P1-15-03 Preoperative endocrine treatment with letrozole ± triptorelin in patients with ER (estrogen receptor) and PgR (progesterone receptor) positive locally advanced breast cancer
Mazza M, Luini A, Veronesi P, Intra M, Bagnardi V, Sangalli F, Iorfida M, Munzone E, Colleoni M. European Institute of Oncology, Milan, Italy.
  Treatment: Bone Metastases
P1-16-01 Skeletal-related events (SRE) prevented in breast cancer patients with bone metastases in the United States (US)
Arellano J, Chen K, Halperin M, Danese M. Amgen Inc., Thousand Oaks, CA; Outcomes Insights, Inc., Westlake Village, CA.
  Treatment: Male Breast Cancer
P1-17-01 Whole genome methylation patterns in male and female breast cancer – Unexpected findings
Johansson I, Lauss M, Holm K, Nilsson C, Fjällskog M-L, Ringnér M, Hedenfalk I. Lund University, Lund, Sweden; Uppsala University, Uppsala, Sweden.
P1-17-02 Male breast carcinoma: A clinicopathological and immunohistochemical characterization study
Zhou R, Yu L, Yu B, Zhou S, Bi R, Shui R, Lu H, Cai X, Yang W. Fudan University Shanghai Cancer Center, Shanghai, China; Shanghai Medical College, Fudan University, Shanghai, China.
Home | About SABCS | Press Releases | Media | Event Photos | Past Symposia | Satellite Symposia | Patient Advocates | FAQs | Contact Us
Registration | Hotel | Support & Exhibits | 2014 Overview | Program | Travel & Transportation

Rich Markow, Director, Symposia
Cancer Therapy & Research Center at UT Health Science Center San Antonio

7979 Wurzbach Road, MC 8224 San Antonio, TX 78229 USA
Phone: 210-450-1550    Fax: 210-450-1560    Email: sabcs@uthscsa.edu
Copyright © 2014 SABCS. All rights reserved. - Privacy Policy